Strategic Market Novian Health is a late-stage medical device company with a focus on image-guided laser therapy for breast tumors, holding CE Mark and pursuing U.S. clearance. Potential sales opportunity: partner with clinical centers and breast radiology teams in Europe and the U.S. to accelerate adoption of Novilase for malignant, benign, and soft tissue ablation.

Expansion Potential Existing European commercialization and a U.S. pivotal trial indicate dual-market expansion. Sales outreach should target European breast clinics and U.S. cancer centers participating in early-stage breast cancer trials, highlighting quicker recovery, local anesthesia, and reduced retreatments as differentiators.

Regulatory Momentum CE Mark achieved; FDA Breakthrough Device designation previously awarded; pending 510(k) clearance for malignant breast tumor destruction. Opportunities exist in navigating regulatory-driven adoption with key hospital systems and procurement teams seeking innovative, minimally invasive options.

Clinical Collaboration Active multicenter pivotal trial and existing fibroadenoma clearance present doors to collaborative study sites, surgeon and radiologist partnerships, and co-marketing with trial networks. Focus on expanding budding KOL endorsements to drive wider adoption in breast-conserving therapy.

Fundraising & Partnerships Recent $2.2M convertible note funding and a strong development pipeline position Novian for strategic alliances, distributor agreements, and hospital channel partnerships. Target aligned medical device distributors and health systems seeking next-gen breast tumor ablation technology with compelling patient outcomes.